{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:07Z","timestamp":1786118767142,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adrenocortical carcinoma (ACC) is a highly aggressive malignancy with high recurrence rates and poor prognosis. There are only limited treatment options with poor response rates. ACCs are documented to express chemokine receptor CXCR4, which can be visualized using\n                    <jats:sup>68<\/jats:sup>\n                    Ga-pentixafor PET\/CT. We herein present a case of ACC with local recurrence and peritoneal metastases, which was well visualized on FDG and pentixafor PET\/CT. The high expression of CXCR4 offers the potential of theranostics and targeted endoradiotherapy in patients with metastatic ACC. We also observed thymic rebound to illustrate mild to moderate grade uptake of\n                    <jats:sup>68<\/jats:sup>\n                    Ga-pentixafor in this patient.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005656","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:01:26Z","timestamp":1735556486000},"page":"e286-e287","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["CXCR4\u2014A Potential Novel Theranostic Target in Adrenocortical Carcinoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Amir","family":"Nazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Kalshetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"bib1-20250403","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2967\/jnumed.111.097733","article-title":"CXCR4-based imaging agents","volume":"52","author":"Woodard","year":"2011","journal-title":"J Nucl Med"},{"key":"bib2-20250403","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1007\/s00259-024-06800-z","article-title":"Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma","volume":"51","author":"Schloetelburg","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250403","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcell.2015.00045","article-title":"Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment","volume":"3","author":"Lib\u00e9","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"bib4-20250403","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.597878","article-title":"Impact of the chemokine receptors CXCR4 and CXCR7 on clinical outcome in adrenocortical carcinoma","volume":"11","author":"Chifu","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"bib5-20250403","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00259-023-06547-z","article-title":"CXCR4-directed PET\/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology","volume":"51","author":"Dreher","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250403","first-page":"1687","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-Pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"key":"bib7-20250403","doi-asserted-by":"crossref","first-page":"e0367","DOI":"10.1097\/MD.0000000000010367","article-title":"Rebound thymic hyperplasia after adrenalectomy in a patient with Cushing syndrome caused by adrenocortical adenoma: a case report","volume":"97","author":"Hwang","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:40:51Z","timestamp":1786034451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005656","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"2024-07-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}